The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia

Journal of the American Society of Nephrology

Volumn 27, Issue 1, 2016, Pages 189-201

  Shivanna, Sowmya ^a   Kolandaivelu, Kumaran ^b   Shashar, Moshe ^a   Belghasim, Mostafa ^a   Al Rabadi, Laith ^a   Balcells, Mercedes ^b,c   Zhang, Anqi ^a   Weinberg, Janice ^d   Francis, Jean ^a   Pollastri, Michael P ^e   Edelman, Elazer R ^b   Sherr, David H ^d   Chitalia, Vipul C ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c INSTITUT QUÍMIC DE SARRIÀ   (Spain)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AROMATIC HYDROCARBON RECEPTOR; BIOLOGICAL MARKER; CH 223191; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; INDICAN; MESSENGER RNA; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CELL DAMAGE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; DOWN REGULATION; EMBRYO; END STAGE RENAL DISEASE; ENZYME ACTIVATION; ENZYME INHIBITION; EX VIVO STUDY; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HALF LIFE TIME; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; IN VIVO CULTURE; MALE; MICROENVIRONMENT; MIDDLE AGED; MOUSE; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; RAT; REMISSION; RISK FACTOR; SHEAR STRESS; SIGNAL TRANSDUCTION; THROMBOSIS; UBIQUITINATION; UPREGULATION; UREMIA; VASCULAR SMOOTH MUSCLE CELL; ANTAGONISTS AND INHIBITORS; COMPLICATION; FEMALE; PHYSIOLOGY;

ADULT; FEMALE; HUMANS; INDICAN; MALE; MIDDLE AGED; PROTEIN STABILITY; RECEPTORS, ARYL HYDROCARBON; THROMBOPLASTIN; THROMBOSIS; UREMIA;

EID: 84954444245     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014121241     Document Type: Article

References (41)

1. Casserly LF,Dember LM: Thrombosis in end-stage renal disease. Semin Dial 16: 245-256, 2003
2. Kumar G, Sakhuja A, Taneja A, Majumdar T, Patel J, Whittle J, Nanchal R; Milwaukee Initiative in Critical Care Outcomes Research (MICCOR) Group of Investigators: Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol 7: 1584-1590, 2012
3. Kimura T,Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T,Mitsudo K, Miyazaki S, Yamaguchi T, Hiyoshi E, Nishimura E, Isshiki T; RESTART Investigators: Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 122: 52-61, 2010
4. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A: Incidence, predictors, and outcome of thrombosis after successful implantation of drugeluting stents. JAMA 293: 2126-2130, 2005
5. Belardi JA, Albertal M: Coronary stent thrombosis in patients with chronic kidney disease: Balancing anti-ischemic efficacy and hemorrhagic risk. Catheter Cardiovasc Interv 80: 368-369, 2012
6. Park SH, KimW, Park CS, Kang WY, Hwang SH, KimW: A comparison of clopidogrel responsiveness in patientswith versus without chronic renal failure. Am J Cardiol 104: 1292-1295, 2009
7. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA,HorrowJ, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L: Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122: 1056-1067, 2010
8. Chitalia VC, Shivanna S,Martorell J, Balcells M, Bosch I, Kolandaivelu K, Edelman ER: Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smoothmuscle cell tissue factor. Circulation 127: 365-376, 2013
9. Steffel J, Lüscher TF, Tanner FC: Tissue factor in cardiovascular diseases: Molecularmechanisms and clinical implications. Circulation 113: 722-731, 2006
10. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J; European Uremic Toxin Work Group: A bench to bedside view of uremic toxins. J Am Soc Nephrol 19: 863-870, 2008
11. Jourde-ChicheN, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P: Protein-bound toxins-update 2009. Semin Dial 22: 334-339, 2009
12. Stejskalova L, Dvorak Z, Pavek P: Endogenous and exogenous ligands of aryl hydrocarbon receptor: Current state of art. Curr Drug Metab 12: 198-212, 2011
13. Puga A, Ma C, Marlowe JL: The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol 77: 713-722, 2009
14. Kawajiri K, Kobayashi Y, Ohtake F, Ikuta T, Matsushima Y, Mimura J, Pettersson S, Pollenz RS, Sakaki T, Hirokawa T, Akiyama T, KurosumiM, Poellinger L, Kato S, Fujii-Kuriyama Y: Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc Natl Acad Sci U S A 106: 13481-13486, 2009
15. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, Takahashi S, KouzmenkoA,NoharaK,Chiba T, Fujii-Kuriyama Y, Kato S: Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446: 562-566, 2007
16. Schroeder JC, Dinatale BC, Murray IA, Flaveny CA, Liu Q, Laurenzana EM, Lin JM, Strom SC, Omiecinski CJ, Amin S, Perdew GH: The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 49: 393-400, 2010
17. Bogdanov VY, Osterud B: Cardiovascular complications of diabetes mellitus: The Tissue Factor perspective. Thromb Res 125: 112-118, 2010
18. Parks AJ, Pollastri MP, Hahn ME, Stanford EA, Novikov O, Franks DG, Haigh SE,Narasimhan S, Ashton TD, Hopper TG, Kozakov D, Beglov D, Vajda S, Schlezinger JJ, Sherr DH: In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol 86: 593-608, 2014
19. Zhao B, Degroot DE, Hayashi A, He G, Denison MS: CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor. Toxicol Sci 117: 393-403, 2010
20. Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N, Poitevin S, Arnaud L, Vanholder R, Brunet P, Dignat-George F, Burtey S: Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int 84: 733-744, 2013
21. Chang X, Fan Y, Karyala S, Schwemberger S, Tomlinson CR, Sartor MA, Puga A: Ligand-independent regulation of transforming growth factor beta1 expression and cell cycle progression by the aryl hydrocarbon receptor. Mol Cell Biol 27: 6127-6139, 2007
22. Mackman N: Uremic serum and ubiquitylation of tissue factor. Circulation 127: 320-321, 2013
23. PendurthiUR,Ghosh S,Mandal SK,RaoLV: Tissue factor activation: Isdisulfide bond switching a regulatory mechanism? Blood 110: 3900-3908, 2007
24. Kolandaivelu K, Swaminathan R, GibsonWJ, Kolachalama VB,Nguyen-Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER: Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123: 1400-1409, 2011
25. Shashar M, Francis J, Chitalia V: Thrombosis in the uremic milieuemerging role of "thrombolome". Semin Dial 28: 198-205, 2015
26. Barouki R, Aggerbeck M, Aggerbeck L, Coumoul X: The aryl hydrocarbon receptor system. Drug Metabol Drug Interact 27: 3-8, 2012
27. Yisireyili M, Saito S, Abudureyimu S, Adelibieke Y, Ng HY, Nishijima F, Takeshita K, Murohara T, Niwa T: Indoxyl sulfate-induced activation of (pro)renin receptor promotes cell proliferation and tissue factor expression in vascular smooth muscle cells. PLoS ONE 9: E109268, 2014
28. Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM: Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogenactivated protein kinase signalling pathway. Mol Cell Biol 16: 5839-5845, 1996
29. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J,Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO: The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272: 23843-23850, 1997
30. Capodanno D, Angiolillo DJ: Antithrombotic therapy in patients with chronic kidney disease. Circulation 125: 2649-2661, 2012
31. Basra SS, Tsai P, Lakkis NM: Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol 58: 2263-2269, 2011
32. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb J, Vazquez MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, RoccoMV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI; Dialysis Access ConsortiumStudyGroup: Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial. JAMA 299: 2164-2171, 2008
33. Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, Nagai R, Wilson S, Ingram AJ: Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: A randomized controlled trial. J Am Soc Nephrol 13: 2331-2337, 2002
34. Kolandaivelu K, Leiden BB, Edelman ER: Predicting response to endovascular therapies: Dissecting the roles of local lesion complexity, systemic comorbidity, and clinical uncertainty. J Biomech 47: 908-921, 2014
35. Apetoh L,Quintana FJ, Pot C, JollerN, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK: The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11: 854-861, 2010
36. Quintana FJ, Sherr DH: Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev 65: 1148-1161, 2013
37. Kokubo T, Ishikawa N, Uchida H, Chasnoff SE, Xie X,Mathew S, Hruska KA, Choi ET: CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas. J Am Soc Nephrol 20: 1236-1245, 2009
38. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T: Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 403: 1841-1850, 2012
39. Niwa T: Targeting protein-bound uremic toxins in chronic kidney disease. Expert Opin Ther Targets 17: 1287-1301, 2013
40. Huang ST, Shu KH,ChengCH,WuMJ, YuTM,Chuang YW,ChenCH: Serum total p-cresol and indoxyl sulfate correlated with stage of chronic kidney disease in renal transplant recipients. Transplant Proc 44: 621-624, 2012
41. Vanholder R, Schepers E, Pletinck A, Nagler EV,GlorieuxG: The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: A systematic review.JAm Soc Nephrol 25: 1897-1907, 2014